Research Reports | Market Assessment
July 2014

Otezla (Psoriatic Arthritis) (Wave 1) | LaunchTrends | US | 2014

This LaunchTrends report series will track the post-launch awareness, trial, and usage of Apremilast (Otezla) among rheumatologists for the treatment of Psoriatic Arthritis. Three waves of the syndicated report will assess physician perceptions at one month, six months and one year after the launch of Apremilast. The reports will further explore where Apremilast is being placed in the treatment algorithm and in which patient types, strengths and weaknesses of the product profile compared to other agents, and the overall impact of the launch on the market landscape.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports